tbuckley/cabot-search huggingface dataset:
Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series — 465 Health Care Facilities, United States, December 2020–October 2021
Authors: Christina Yek, Sarah Warner, Jennifer L. Wiltz, Junfeng Sun, Stacey Adjei, Alex Mancera, Benjamin J. Silk, Adi V. Gundlapalli, Aaron M. Harris, Tegan K. Boehmer, Sameer S. Kadri
Journal: MMWR Morbidity and Mortality Weekly Report (2022)

Vaccination against SARS-CoV-2, the virus that causes COVID-19, is highly effective at preventing COVID-19-associated hospitalization and death; however, some vaccinated persons might develop COVID-19 with severe outcomes† (1,2). Using data from 465 facilities in a large U.S. health care database, this study assessed the frequency of and risk factors for developing a severe COVID-19 outcome after completing a primary COVID-19 vaccination series (primary vaccination), defined as receipt of 2 doses of an mRNA vaccine (BNT162b2 [Pfizer-BioNTech] or mRNA-1273 [Moderna]) or a single dose of JNJ-78436735 [Janssen (Johnson & Johnson)] ≥14 days before illness onset. Severe COVID-19 outcomes were defined as hospitalization with a diagnosis of acute respiratory failure, need for noninvasive ventilation (NIV), admission to an intensive care unit (ICU) including all persons requiring invasive mechanical ventilation, or death (including discharge to hospice). Among 1,228,664 persons who completed primary vaccination during December 2020-October 2021, a total of 2,246 (18.0 per 10,000 vaccinated persons) developed COVID-19 and 189 (1.5 per 10,000) had a severe outcome, including 36 who died (0.3 deaths per 10,000). Risk for severe outcomes was higher among persons who were aged ≥65 years, were immunosuppressed, or had at least one of six other underlying conditions. All persons with severe outcomes had at least one of these risk factors, and 77.8% of those who died had four or more risk factors. Severe COVID-19 outcomes after primary vaccination are rare; however, vaccinated persons who are aged ≥65 years, are immunosuppressed, or have other underlying conditions might be at increased risk. These persons should receive targeted interventions including chronic disease management, precautions to reduce exposure, additional primary and booster vaccine doses, and effective pharmaceutical therapy as indicated to reduce risk for severe COVID-19 outcomes. Increasing COVID-19 vaccination coverage is a public health priority.
Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity
Authors: Yash Agarwal, Lauren E. Milling, Jason Y. H. Chang, Luciano Santollani, Allison Sheen, Emi A. Lutz, Anthony Tabet, Jordan Stinson, Kaiyuan Ni, Kristen A. Rodrigues, Tyson J. Moyer, Mariane B. Melo, Darrell J. Irvine, K. Dane Wittrup
Journal: Nature Biomedical Engineering (2022)
Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting
Authors: John E Gorzynski, Sneha D Goenka, Kishwar Shafin, Tanner D Jensen, Dianna G Fisk, Megan E Grove, Elizabeth Spiteri, Trevor Pesout, Jean Monlong, Gunjan Baid, Jonathan A Bernstein, Scott Ceresnak, Pi-Chuan Chang, Jeffrey W Christle, Henry Chubb, Karen P Dalton, Kyla Dunn, Daniel R Garalde, Joseph Guillory, Joshua W Knowles, Alexey Kolesnikov, Michael Ma, Tia Moscarello, Maria Nattestad, Marco Perez, Maura R Z Ruzhnikov, Mehrzad Samadi, Ankit Setia, Chris Wright, Courtney J Wusthoff, Katherine Xiong, Tong Zhu, Miten Jain, Fritz J Sedlazeck, Andrew Carroll, Benedict Paten, Euan A Ashley
Journal: New England Journal of Medicine (2022)
Error in a Supplement
Authors: Divya Gupta, J Lee, Alberty Lin, Nuh Rahbari, Emrullah Birgin, Jürgen Weitz
Journal: JAMA Surgery (2021)

Xavier Benoit D’Journo, MD, PhD; David Boulate, MD, PhD; Alex Fourdrain, MD; Anderson Loundou, MD, PhD; Mark I. van Berge Henegouwen, MD, PhD; Suzanne S. Gisbertz, MD, PhD; J. Robert O’Neill, MD; Arnulf Hoelscher, MD; Guillaume Piessen, MD, PhD; Jan van Lanschot, MD, PhD; Bas Wijnhoven, MD, PhD; Blair Jobe, MD; Andrew Davies, MD; Paul M. Schneider, MD; Manuel Pera, MD, PhD; Magnus Nilsson, MD, PhD; Philippe Nafteux, MD, PhD; Yuko Kitagawa, MD, PhD; Christopher R. Morse, MD; Wayne Hofstetter, MD; Daniela Molena, MD; Jimmy Bok-Yan So, MD; Arul Immanuel, MD; Simon L. Parsons, MD, PhD; Michael Hareskov Larsen, MD; James P. Dolan, MD; Stephanie G. Wood, MD; Nick Maynard, MD; Mark Smithers, MD; Sonia Puig, MD; Simon Law, MS, PhD; Ian Wong, MD; Andrew Kennedy, MD; Wang KangNing, MD, PhD; John V. Reynolds, MCh, MD; C.S. Pramesh, MS; Mark Ferguson, MD; Gail Darling, MD; Wolfgang Schröder, MD; Marc Bludau, MD; Tim Underwood, MD, PhD; Richard van Hillegersberg, MD, PhD; Andrew Chang, MD; Ivan Cecconello, MD, PhD; Ulysses Ribeiro Jr, MD, PhD; Giovanni de Manzoni, MD, PhD; Riccardo Rosati, MD, PhD; MadhanKumar Kuppusamy, MD; Pascal Alexandre Thomas, MD, PhD; Donald E. Low, MD; International Esodata Study Group; Geoffrey Brioude; Delphine Trousse; Egle Jezerskyte, ; Wietse J Eshuis; Richard Hardwick; Peter Safranek; John Bennett; Andrew Hindmarsh; Vijay Sujedran ; Martin Hemmerich; Margerite Messier; Sebastien Degissors; Frederiek Nuytens; Christophe mariette; Sjoerd M Lagarde; Ali H Zaidi; Janine Zylstra; James Gossage; Cara Baker; Mark Kelly; Simone Schillinger; Marta Gimeno; Fredrik Klevebro; Masaru Hayami; Toni Lerut; Johnny Moons; Hirofumi Kawakubo; Satoru Matsuda; Yuki Hirata; Julie Garrity; Huawei Tang; Manjit Bains; Joe Dycoco; Kristen Busalacchi; Rebecca Carr; David R Jones; Asim Shabbir; Michael Griffin; Helen Jaretzke; Neil T Welch; Ravinder Vohra; James A Catton; John H Saunders; Fadi Yanni; Daniela Zanotti; Pritam Singh; Larsen Nicolaj; Marcus Stilling; Charlie C Borzy; Kayla Siemens; John Findlay; Stephen Ash; Iain Thomson; Andrew Barbour; Janine Thomas; John Whiting; Jeannette Kwok; Raymond Kennedy; Fang Qiang; Han YongTao; Penh Lin; Xiao WenGuang; Sinead King; Ravinder Narayanasamy; Apurva Ashok; Amy Durkin-Celauro; Catherine Staub; Emma Small; Christiane J Bruns; James Byrne; Jamie Kelly; Fergus Noble; Donna Sharland; Rachel Fraser; Rob Walker; Saqib Rahman; Ben Grace; Jelle Ruurda; Sylvia Van der Host; Arjen Van der Veen; Gino Kuiper; Judy Miller; Shari Barnett; Rubens AA Sallum; Jacopo Weindelmayer; Carlo Alberto De Pasqual; Paolo Parisse; Andrea Cossu; Francesco Puccetti; Simonetta Massaron; Bonnie Marston
Lessons Learned From 10 Years of Preschool Intervention for Health Promotion
Authors: Gloria Santos-Beneit, Rodrigo Fernández-Jiménez, Amaya de Cos-Gandoy, Carla Rodríguez, Vanesa Carral, Patricia Bodega, Mercedes de Miguel, Xavier Orrit, Domenec Haro, José L. Peñalvo, Juan Miguel Fernández-Alvira, Carles Peyra, Jaime A. Céspedes, Alexandra Turco, Marilyn Hunn, Risa Jaslow, Jorge Baxter, Isabel Carvajal, Valentin Fuster
Journal: Journal of the American College of Cardiology (2022)

Implementing a health promotion program for children is a complex endeavor. In this review, we outline the key lessons learned over 10 years of experience in implementing the SI! Program (Salud Integral–Comprehensive Health) for cardiovascular health promotion in preschool settings in 3 countries: Colombia (Bogotá), Spain (Madrid), and the United States (Harlem, New York). By matching rigorous efficacy studies with implementation science, we can help bridge the divide between science and educational practice. Achieving sustained lifestyle changes in preschool children through health promotion programs is likely to require the integration of several factors: 1) multidisciplinary teams; 2) multidimensional educational programs; 3) multilevel interventions; 4) local program coordination and community engagement; and 5) scientific evaluation through randomized controlled trials. Implementation of effective health promotion interventions early in life may induce long-lasting healthy behaviors that could help to curb the cardiovascular disease epidemic.
Re: Bernardo Rocco, Luca Sarchi, Simone Assumma, et al. Digital Frozen Sections with Fluorescence Confocal Microscopy During Robot-assisted Radical Prostatectomy: Surgical Technique. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.021
Authors: Eoin Dinneen, Jon Oxley, Greg Shaw
Journal: European Urology (2021)
The effect of inotropic state on the suze of the mitral annulus Joseph H. Gorman, III, Robert C. Gorman, Benjamin M. Jackson, Martin St. John-Sutton, Theodore Plappert, T. Sloane Guy, IV, Sina Moainei, L. Henry admunds, Jr., Universtiy of Pennsylvania School of Medicine, Philadelphia, PA
Journal: Journal of the American College of Cardiology (2001)
Association between Environmental Quality Index and metastatic pancreatic cancer.
Authors: Muhammet Ozer, Suleyman Yasin Goksu, Jude Khatib, Salwan Al Mutar, Todd Anthony Aguilera, Herbert Zeh, Muhammad Shaalan Beg, Syed Mohammad Ali Kazmi
Journal: Journal of Clinical Oncology (2022)

521 Background: Pancreatic cancer ranks as the 3 rd leading cause of cancer mortality. Overall more than 50% of patients have metastatic disease at diagnosis. In this study, we evaluated the association between the national level Environmental Quality Index (EQI) and metastatic pancreatic cancer in the US. Methods: Adult patients with pancreatic cancer in the SEER database from 2010-2016 were included in this study. The unknown stage was excluded. Patients were categorized into two groups: metastatic vs. non-metastatic disease. EQI provides county-level environmental quality data from 2005-2010 and presents five domains (built, sociodemographic, air, water, land). EQI was categorized into quintiles, with the 5 th quantile representing a poorer environmental quality. We used the multivariable logistic regression analysis to assess the association between EQI quintiles and metastatic pancreatic cancer adjusting by age, gender, and race (White, Black, and Others). In addition, the SEER*Stat was used to evaluate the age-adjusted incidence rate, and the correlation coefficient between EQI domains and incidence rate was calculated. Results: A total of 75,461 pancreatic cancer patients were included; 55% had metastatic disease. In the adjusted multivariable analysis, metastatic pancreatic cancer was associated with poor built EQI (OR 1.06 [1.01-1.11]). Among metastatic pancreatic cancer patients, poor overall EQI was strongly associated with age &gt; 50 years (OR 1.06 [1.01-1.11]) and Black race (OR 1.29 [1.10-1.51]). Lower built EQI domain was associated with &gt; 50 (OR 1.07 [1.02-1.12]) and White race (OR 1.07 [1.02-1.12]). The incidence rate of metastatic pancreatic cancer was positively correlated with total EQI (rho=0.02, p&lt;0.001), sociodemographic EQI (rho=0.23, p&lt;0.001), land EQI (rho=0.14, p&lt;0.001), and air EQI (rho=0.34, p&lt;0.001). Conclusions: Using population-based environmental data, we found built EQI to be associated with metastatic pancreatic cancer. Among metastatic pancreatic cancer patients, total environmental quality was associated with older age at diagnosis and the Black race, while built EQI domain was associated with older age at diagnosis and the White race. Environmental quality was positively correlated with the incidence rate of metastatic pancreatic cancer.[Table: see text]
Association of Telomere Length With Risk of Disease and Mortality
Authors: Carolin V. Schneider, Kai Markus Schneider, Alexander Teumer, Karl Lenhard Rudolph, Daniel Hartmann, Daniel J. Rader, Pavel Strnad
Journal: JAMA Internal Medicine (2022)

<h3>Importance</h3> Telomeres protect DNA from damage. Because they shorten with each mitotic cycle, leukocyte telomere length (LTL) serves as a mitotic clock. Reduced LTL has been associated with multiple human disorders. <h3>Objective</h3> To determine the association between LTL and overall as well as disease-specific mortality and morbidity. <h3>Design, Setting, and Participants</h3> This multicenter, community-based cohort study conducted from March 2006 to December 2010 included longitudinal follow-up (mean [SD], 12 [2] years) for 472 432 English participants from the United Kingdom Biobank (UK Biobank) and analyzed morbidity and mortality. The data were analyzed in 2021. <h3>Main Outcomes and Measures</h3> Hazard ratios (HRs) and odds ratios for mortality and morbidity associated with a standard deviation change in LTL, adjusted for age, sex, body mass index (calculated as weight in kilograms divided by height in meters squared), and ethnicity. <h3>Results</h3> This study included a total of 472 432 English participants, of whom 54% were women (mean age, 57 years). Reduced LTL was associated with increased overall (HR, 1.08; 95% CI, 1.07-1.09), cardiovascular (HR, 1.09; 95% CI, 1.06-1.12), respiratory (HR, 1.40; 95% CI, 1.34-1.45), digestive (HR, 1.26; 95% CI, 1.19-1.33), musculoskeletal (HR, 1.51; 95% CI, 1.35-1.92), and COVID-19 (HR, 1.15; 95% CI, 1.07-1.23) mortality, but not cancer-related mortality. A total of 214 disorders were significantly overrepresented and 37 underrepresented in participants with shorter LTL. Respiratory (11%), digestive/liver-related (14%), circulatory (18%), and musculoskeletal conditions (6%), together with infections (5%), accounted for most positive associations, whereas (benign) neoplasms and endocrinologic/metabolic disorders were the most underrepresented entities. Malignant tumors, esophageal cancer, and lymphoid and myeloid leukemia were significantly more common in participants with shorter LTL, whereas brain cancer and melanoma were less prevalent. While smoking and alcohol consumption were associated with shorter LTL, additional adjustment for both factors, as well as cognitive function/major comorbid conditions, did not significantly alter the results. <h3>Conclusions and Relevance</h3> This cohort study found that shorter LTL was associated with a small risk increase of overall mortality, but a higher risk of mortality was associated with specific organs and diseases.
Correction: Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kγ to Promote Pancreatic Cancer Metastasis
Authors: Xiaofeng Wang, Guangtao Luo, Kundong Zhang, Jun Cao, Chen Huang, Tao Jiang, Bingya Liu, Liping Su, Zhengjun Qiu
Journal: Cancer Research (2020)

In the original version of [this article][1] ([1][2]), the image depicting the effect of macrophages treated with PANC-1-H-exo and transfected with PI3Kγ siRNA on pancreatic cancer cells invasion in the bottom left panel of Fig. 5L is incorrect. The error has been corrected in the latest online
Divergent roles of haptoglobin and hemopexin deficiency for disease progression of Shiga-toxin–induced hemolytic-uremic syndrome in mice
Authors: Wiebke Pirschel, Antonio N. Mestekemper, Bianka Wissuwa, Nadine Krieg, Sarah Kröller, Christoph Daniel, Florian Gunzer, Emanuela Tolosano, Michael Bauer, Kerstin Amann, Stefan H. Heinemann, Sina M. Coldewey
Journal: Kidney International (2022)

Thrombotic microangiopathy, hemolysis and acute kidney injury are typical clinical characteristics of hemolytic-uremic syndrome (HUS), which is predominantly caused by Shiga-toxin-producing Escherichia coli. Free heme aggravates organ damage in life-threatening infections, even with a low degree of systemic hemolysis. Therefore, we hypothesized that the presence of the hemoglobin- and the heme-scavenging proteins, haptoglobin and hemopexin, respectively impacts outcome and kidney pathology in HUS. Here, we investigated the effect of haptoglobin and hemopexin deficiency (haptoglobin-/-, hemopexin-/-) and haptoglobin treatment in a murine model of HUS-like disease. Seven-day survival was decreased in haptoglobin-/- (25%) compared to wild type mice (71.4%), whereas all hemopexin-/- mice survived. Shiga-toxin-challenged hemopexin-/- mice showed decreased kidney inflammation and attenuated thrombotic microangiopathy, indicated by reduced neutrophil recruitment and platelet deposition. These observations were associated with supranormal haptoglobin plasma levels in hemopexin-/- mice. Low dose haptoglobin administration to Shiga-toxin-challenged wild type mice attenuated kidney platelet deposition and neutrophil recruitment, suggesting that haptoglobin at least partially contributes to the beneficial effects. Surrogate parameters of hemolysis were elevated in Shiga-toxin-challenged wild type and haptoglobin-/- mice, while signs for hepatic hemoglobin degradation like heme oxygenase-1, ferritin and CD163 expression were only increased in Shiga-toxin-challenged wild type mice. In line with this observation, haptoglobin-/- mice displayed tubular iron deposition as an indicator for kidney hemoglobin degradation. Thus, haptoglobin and hemopexin deficiency plays divergent roles in Shiga-toxin-mediated HUS, suggesting haptoglobin is involved and hemopexin is redundant for the resolution of HUS pathology.
Educational program in nuclear medicine technology
Authors: G. H. Simmons
Journal: JAMA (1971)

The shortage of qualified technologists and technicians in nuclear medicine is a serious problem. The urgent need is not only for additional people, but for more highly qualified ones capable of performing technical functions with a minimum of direct supervision, thereby allowing the physician to concentrate more on activities that require his medical skill and judgement. The National Advisory Committee on Radiation in its April 1966 report to the Surgeon General of the Public Health Service stated the problem in the following words: "In the field of technological manpower, serious difficulties currently prevail in the provision of adequate numbers of clinical X-ray and Nuclear Laboratory Technologists in the United States."<sup>1</sup>The Committee recommended that the Public Health Service should undertake "a series of training programs to provide increasing numbers of technologists in the several disciplines of the Radiological Sciences." As one step toward meeting this challenge, the Public Health
LAW &amp;amp; MEDICINE
Authors: Angela Roddey Holder
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Results and Table
Authors: Divya Gupta, J Lee, Alberty Lin, Nuh Rahbari, Emrullah Birgin, Jürgen Weitz
Journal: JAMA Surgery (2021)

Najia Azhar, MD; Anette Johanssen, MD; Tove Sundström, MD; Joakim Folkesson, MD, PhD; Conny Wallon, MD, PhD; Hartvig Kørner, MD, PhD; Ljiljana Blecic, MD; Håvard Mjørud Forsmo, MD, PhD; Tom Øresland, MD, PhD; Sheraz Yaqub, MD, PhD; Pamela Buchwald, MD, PhD; Johannes Kurt Schultz, MD, PhD; SCANDIV Study Group
The Cover
Authors: M. Therese Southgate
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phototherapy, Not Photography
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal